Gilead to pay $120 million for kinase biology company

Saturday 26 June 2010

Gilead Sciences Inc has agreed to pay up to $120 million to acquire CGI Pharmaceuticals Inc, a privately-held US company with a library of small molecule kinase inhibitors. CGI’s lead preclinical compound may have application in RA.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States